29 March 2021 in NeuroMolecular Medicine
1 January 2013 in Evidence-Based Complementary and Alternative Medicine
Rhizoma coptidis, the root ofCoptis chinensis Franch, has been used in China as a folk medicine in the treatment of diabetes for thousands of years. Berberine, one of the active ingredients ofRhizoma coptidis, has been reported to improve symptoms of diabetes and to treat experimental cardiac hypertrophy, respectively. The objective of this study was to evaluate the potential effect of berberine on cardiomyocyte hypertrophy in diabetes and its possible influence on peroxisome proliferator-activated receptor-α(PPARα)/nitric oxide (NO) signaling pathway. The cardiomyocyte hypertrophy induced by high glucose (25.5 mmol/L) and insulin (0.1 μmol/L) (HGI) was characterized in rat primary cardiomyocyte by measuring the cell surface area, protein content, and atrial natriuretic factor mRNA expression level. Protein and mRNA expression were measured by western blot and real-time RT-PCR, respectively. The enzymatic activity of NO synthase (NOS) was measured using a spectrophotometric assay, and NO concentration was measured using the Griess assay. HGI significantly induced cardiomyocyte hypertrophy and decreased the expression of PPARαand endothelial NOS at the mRNA and protein levels, which occurred in parallel with declining NOS activity and NO concentration. The effect of HGI was inhibited by berberine (0.1 to 100 μmol/L), fenofibrate (0.3 μmol/L), orL-arginine (100 μmol/L). MK886 (0.3 μmol/L), a selective PPARαantagonist, could abolish the effects of berberine and fenofibrate.-nitro-L-arginine-methyl ester (100 μmol/L), a NOS inhibitor, could block the effects ofL-arginine, but only partially blocked the effects of berberine. These results suggest that berberine can blunt HGI-induced cardiomyocyte hypertrophyin vitro, through the activation of the PPARα/NO signaling pathway.
11 October 2023 in IUBMB Life
2 December 2023 in Archives of Biochemistry and Biophysics
30 September 2022 in Research Square
Glioma is a brain tumor that originated from brain or spine glial cells. Despite utilizing alternative treatments, the overall survival remains poor. Oridonin (ORI) is purified from the Chinese herb Rabdosia rubescens which exhibited anti-cancer effects on human tumorigenesis. The aim of this study was to investigate the effect of ORI on U87MG glioblastoma cells and whether Hippo/YAP-related signaling pathway was involved in. Here, we found that ORI inhibited cell proliferation and promoted cell apoptosis in a dose-dependent manner in U87MG cells. Moreover, ORI inhibited Bcl-2, YAP, c-Myc protein expression but increased Bax, caspase-3, p-YAP protein expression. Furthermore, these anti-cancer effects of ORI were also confirmed in a mouse model bearing glioma. Further study suggested that the YAP inhibitor Verteporfin (VP) showed the similar effect of ORI, but ORI reversed the effect of over-expression of YAP. Collectively, Oridonin suppressed glioblastoma oncogenesis via the Hippo/YAP signaling pathway and could be a potential therapeutic target in the treatment of glioblastoma.